We Are Lumira Ventures

Performance is More Than Just Great Returns To Our Investors. It Is Also Measured By Impact.

Lumira Capital Venture Capital in Canada
Over 1 Billion Patients Lives Touched
Venture capital Canada
40+ Diseases Targeted
Lumira Biotech Venture Capital Firm Canada
50+ Approved Products
Ontario Venture Capital Life Sciences
100+ Companies Funded
Venture Capital Life Sciences
$6+ Billion Capital Raised by Portfolio Companies

Approved Products From Our Portfolio

Hepatitis C
Hepatitis C
Cystic Fibrosis
Kidney Disease
Hemophilia B
Lupus
Rheumatoid Arthritis
Asthma
Ophthalmology
Cancer Radiotherapy
Cancer
WHIM Syndrome
Metastatic Cancer
Parkinson’s Disease
Lung Cancer
Rheumatoid Arthritis
Cerebral Palsy
Glaucoma
Pain
Postherpetic Neuralgia
Cataract Surgery
Type 2 Diabetes
Breast Cancer
Wound Care
Heart Failure
Breast Cancer
Prostate Cancer
Liver Cancer
Knee and Hip Repair
Heart Failure
Arrhythmia
Heart Failure
Spinal Disc Disease
Lung Cancer
Peripheral & Coronary Artery Disease
Cardiovascular Disease

Investing With Purpose

Mission-Driven Founders

We partner with founders and diverse teams that are passionate about delivering transformative therapeutic products for patients.

Value Adding Relationships

We are engaged partners, leveraging the strength of our experience and broad network, to work closely with co-investors and management teams to maximize the value, growth, and impact of our companies.

The Right Way

We ensure each investment is done the right way - based on a process of sound diligence, collaboration, and encouraging alternative views, while ultimately being tied to a consensus decision that aligns with our investment objectives.

Strategic Partners

We utilize the deep relationships within our network to facilitate our due diligence and value-added processes, to provide our companies with the incremental insights, tools, and opportunities they need to succeed.

Our Focus

  • Modality: Therapeutic products and medical devices
  • Stage: Across the development continuum for therapeutics and late clinical to revenue generating for medical device
  • Therapeutic Area: We invest in a broad range of indications with high unmet clinical need

Our History

2007

Partners complete a management buyout of MDS Capital and rebrand as Lumira Ventures

2012

Lumira Ventures Fund II (C$121M)

Merck Lumira Biosciences Strategic Fund (C$42M)

2018

Lumira Ventures Fund III (C$178M)

First VC to allocate 10% carry to hospital foundations

2020

Launched the Lumira Venture Innovation Program (VIP)

Established the Lumira Foundation

2021

Lumira Ventures Fund IV (US$222M;C$295M)

Angelini Lumira Biosciences Strategic Fund (US$35M;C$47M)

 

The Lumira Foundation

The mission of the Lumira Foundation is to support community-based initiatives where we live, work and invest. Each initiative we support is identified by a member of our team, portfolio company, and/or our investors, with a focus on actively engaging with those stakeholders, and addressing prevalent and ongoing social needs in communities throughout the areas where we work and invest.

Who We Support
Scroll to Top